^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KITE-585

i
Other names: BCMA CAR T-cell therapy, KITE 585, KITE-585
Associations
Trials
Company:
Gilead
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
7ms
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Mar 2041 --> Dec 2040 | Trial primary completion date: Mar 2041 --> Dec 2040
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
over1year
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells (clinicaltrials.gov)
P2, N=700, Enrolling by invitation, Kite, A Gilead Company | Trial completion date: Nov 2026 --> Mar 2041 | Trial primary completion date: Nov 2026 --> Mar 2041
Trial completion date • Trial primary completion date
|
Yescarta (axicabtagene ciloleucel) • Tecartus (brexucabtagene autoleucel) • KITE-222 • KITE-363 • KITE-439 • KITE-585 • KITE-718
over3years
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. (PubMed, Am J Cancer Res)
Patients underwent leukapheresis and subsequently received a 3-day conditioning therapy regimen (cyclophosphamide [300 mg/m/day] and fludarabine [30 mg/m/day]). Median peak CAR T-cell expansion was low (0.98 cells/μL), as were median peak serum levels of CAR-associated cytokines, including interferon-γ (61.45 pg/mL) and interleukin-2 (0.9 pg/mL). KITE-585 demonstrated a manageable safety profile; however, the limited CAR T-cell expansion and associated lack of anti-tumor response in patients with RRMM treated with KITE-585 is consistent with the minimal CAR T-cell activity observed.
Clinical • P1 data • Journal • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2)
|
fludarabine IV • KITE-585